Description:

AMC-046 Enrollment Form (ENR) Segment B Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus NCT00550589 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3BC16E2A-1483-2256-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3BC16E2A-1483-2256-E044-0003BA3F9857

Keywords:

Clinical Trial

Anus Neoplasms

Eligibility Determination

8/26/12 8/26/12 -
3/19/15 3/19/15 - Martin Dugas

Uploaded on:

March 19, 2015

DOI:

To request one please log in.

License :

Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Cidofovir HIV (NCT00550589)

Details

No Instruction available.

1 forms

StudyEvent: AMC-046 Enrollment Form (ENR) Segment B
1. No Instruction available.

Header Module

Principal Investigator

Projected Start Date of Treatment

mm/dd/yyyy

Comments

Inclusion Criteria

Will The Participant Practice Adequate Birth Control To Prevent Pregnancy While Receiving Treatment And For Three Months After Treatment Is Discontinued (Will the participant practice adequate birth control to prevent pregnancy while receiving treatment and for three months after treatment is discontinued)

Does (do) The Perianal Lesion(s) Have A Surface Area Of At Least 3 Square Centimeters (Does (Do) the perianal lesion(s) have a surface area of at least 3 square centimeters)

Does The Participant Have A Biopsy-proven Perianal Hsil Within 12 Weeks Of Study Entry (Does the participant have a biopsy-proven perianal HSIL within 12 weeks of study entry)

Date Of Biopsy (Date of biopsy)

13 more items in the detailed view.

Karnofsky Performance Status

Date of Biopsy

Exclusion Criteria

Has The Subject Received Topical Treatment For Perianal Dysplasia Within 4 Weeks Of Study Entry (Has the subject received topical treatment for perianal dysplasia within 4 weeks of study entry)

Does The Participant Have Acute, Active Opportunistic Infection (other Than Oral Thrush, Yeast Vaginitis, Or Genital Herpes) Within The Last 14 Days (Does the participant have acute, active opportunistic infection (other than oral thrush, yeast vaginitis, or genital herpes) within the last 14 days)

Is The Participant Receiving Acute Treatment For An Infection (other Than Oral Thrush, Yeast Vaginitis Or Genital Herpes) Or Other Serious Medical Illness Within 14 Days Of Study Entry (Is the participant receiving acute treatment for an infection (other than oral thrush, yeast vaginitis or genital herpes) or other serious medical illness within 14 days of study entry)

Back to the top of the page

Similar models

Show recommended models